714971-28-5

Basic information

• Product Name: 3(S)-HYDROXYMETHYL-4-BOCMORPHOLINE
• Synonyms: 3(S)-HYDROXYMETHYL-4-BOCMORPHOLINE;(S)-N-BOC-3-(HYDROXYMETHYL)MORPHOLINE;(S)-3-Hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester;tert-Butyl (3S)-3-(hydroxymethyl)morpholine-4-carboxylate;(S)-4-Boc-3-hydroxymethyl-morpholine;(S)-tert-butyl 3-(hydroxymethyl)morpholine-4-carboxylate;(3S)-3-(Hydroxymethyl)-4-morpholinecarboxylic Acid 1, 1-Dimethylethyl Ester;1,1-dimethylethyl (3S)-3-(hydroxymethyl)morpholine-4-carboxylate
• CAS NO: 714971-28-5
• Molecular Formula: C₁₀H₁₉NO₄
• Molecular Weight: 217.26
• Product Categories: pharmacetical;Chiral Reagents;Heterocycles;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 714971-28-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 80 ºC
• Boiling Point: 320.7 °C at 760 mmHg
• Flash Point: 147.8 °C
• Appearance: White/Powder
• Density: 1.118
• Vapor Pressure: 2.53E-05mmHg at 25°C
• Refractive Index: 1.474
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 14.85±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 3(S)-HYDROXYMETHYL-4-BOCMORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3(S)-HYDROXYMETHYL-4-BOCMORPHOLINE(714971-28-5)
• EPA Substance Registry System: 3(S)-HYDROXYMETHYL-4-BOCMORPHOLINE(714971-28-5)

Safety Data

• Hazardous Substances Data: 714971-28-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H19NO4/c1-10(2,3)15-9(13)11-4-5-14-7-8(11)6-12/h8,12H,4-7H2,1-3H3/t8-/m0/s1

Upstream product

• 211053-50-8 (S)-3-(hydroxymethyl)morpholine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1373883-17-0 (S)-2-chloroacetylamino-3-hydroxypropionic acid ethyl ester 
• 869681-70-9 (R)-morpholine-3,4-dicarboxylic acid 4-tert-butyl ester 
• 885321-34-6 (R)-3-(tert-butyldiphenylsilyloxymethyl)morpholine 

Downstream Products

• 911223-07-9 (R)-3-{4-chloro-2-[3-(5-methyl-pyrazin-2-yl)-ureido]-phenoxymethyl}-morpholine-4-carboxylic acid tert-butyl ester 
• 911223-06-8 (R)-3-(2-amino-4-chloro-phenoxymethyl)-morpholine-4-carboxylic acid tert-butyl ester 

Relevant articles and documents

POTENT HUMAN NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS

Disclosed are 2-aminopyridine derivative compounds for use as inhibitors of nitric oxide synthase (NOS). In particular, the field of the invention relates to 2-aminopyridine derivative compounds for use as inhibitors of neuronal nitric oxide synthase (nNOS), which are formulated as pharmaceutical compositions for treating diseases and disorders associated with nNOS such as Alzheimer's, Parkinson's, and Huntington's diseases, and amytrophic lateral sclerosis, cerebral palsy, stroke/ischemic brain damage, and migraine headaches.

Chiral 3 - morpholine methyl alcohol and 3 - morpholine a acid preparation method of the compound

The invention discloses a novel method for preparing chiral 3-morpholine methanol and 3-morpholine formic acid compounds. The method comprises the following steps: taking chiral serine as an initial material to obtain a serine ester (III) from a catalyst by esterification; reacting with halogen acetyl halide under an alkaline condition to obtain a compound (IV); obtaining a compound (V) by hydroxyl protection; adding a reducing agent to restore the ester into alcohol (VI); carrying out cyclization under the alkaline condition to obtain a compound (VII); obtaining a target product chiral 3-morpholine methanol compound (I) by amide reduction, hydroxyl deprotection and N protection; obtaining a chiral 3-morpholine formic acid compound (II) by oxidation. The method has the advantages of being low in cost, friendly to environment, simple to operate, high in yield, high in product purity and the like, the used reagent is simple and safe, and an intermediate in the reaction of each step does not need to be further purified, so that the experiment operation is greatly simplified, the production cost is reduced, and the method is applicable to industrial production.

HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl

Substituted urea compounds useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division, also are disclosed.